Pulse Biosciences(PLSE)
$44.41-1.42 (-3.10%)
PLSE
Pulse Biosciences financials statements
$44.41
At close:-1.42 (-3.10%)
Want to see PLSE full AI Analyst Report?
Pulse Biosciences (PLSE) Ratios
292 Followers
Pulse Biosciences Ratios
PLSE's free cash flow for Q3 2026 was $-15.41M. For the 2026 fiscal year, PLSE's free cash flow was decreased by $-142.00K and operating cash flow was $-15.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.53 | 11.88 | 6.76 | 10.39 | 4.30 |
| Quick Ratio | 10.51 | 11.88 | 6.76 | 10.39 | 3.62 |
| Cash Ratio | 10.19 | 11.74 | 6.61 | 10.22 | 3.36 |
| Solvency Ratio | -5.17 | -2.98 | -2.77 | -0.71 | -3.37 |
| Operating Cash Flow Ratio | -6.83 | -3.61 | -4.93 | -7.86 | -6.35 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -51.27 | -124.08 |
| Net Current Asset Value | $ 69.54M | $ 101.85M | $ 30.53M | $ -17.98M | $ 18.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.07 | 0.15 | 0.98 | 0.21 |
| Debt-to-Equity Ratio | 0.09 | 0.08 | 0.21 | -33.79 | 0.32 |
| Debt-to-Capital Ratio | 0.09 | 0.07 | 0.17 | 1.03 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 1.04 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.15 | 1.33 | -34.64 | 1.52 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -38.52 | -61.83 | -141.90 |
| Interest Coverage Ratio | 0.00 | 0.00 | -39.61 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.70 | 0.00 |
| Interest Debt Per Share | 0.11 | 0.15 | 0.21 | 2.24 | 0.40 |
| Net Debt to EBITDA | 1.02 | 2.08 | 0.83 | -0.26 | 0.28 |
| Profitability Margins | |||||
| Gross Profit Margin | -360.00% | 0.00% | 0.00% | -1606.29% | -38.79% |
| EBIT Margin | -20794.57% | 0.00% | 0.00% | -8293.86% | -4443.86% |
| EBITDA Margin | -20488.57% | 0.00% | 0.00% | -8100.29% | -4363.05% |
| Operating Profit Margin | -21982.57% | 0.00% | 0.00% | -8293.86% | -4443.86% |
| Pretax Profit Margin | -20794.57% | 0.00% | 0.00% | -8357.86% | -4489.42% |
| Net Profit Margin | -20794.57% | 0.00% | 0.00% | -8357.86% | -4489.42% |
| Continuous Operations Profit Margin | -20794.57% | 0.00% | 0.00% | -8357.86% | -4489.42% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.60% | 95.25% | 96.87% | 100.77% | 101.03% |
| Return on Assets (ROA) | -76.99% | -40.45% | -71.36% | -75.12% | -117.35% |
| Return on Equity (ROE) | -90.24% | -46.65% | -95.15% | 2602.54% | -178.37% |
| Return on Capital Employed (ROCE) | -88.83% | -45.96% | -83.08% | -80.75% | -137.80% |
| Return on Invested Capital (ROIC) | -87.25% | -45.46% | -81.44% | -78.77% | -134.24% |
| Return on Tangible Assets | -79.83% | -41.72% | -77.48% | -80.66% | -131.96% |
| Earnings Yield | -7.87% | -5.27% | -7.18% | -62.24% | -15.37% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.28 | 0.00 | 0.00 | 0.00 | 23.25 |
| Payables Turnover | 0.58 | 0.00 | 0.66 | 7.59 | 0.68 |
| Inventory Turnover | 11.84 | 0.00 | 0.00 | 0.00 | 0.34 |
| Fixed Asset Turnover | 0.05 | 0.00 | 0.00 | 0.07 | 0.13 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 |
| Cash Conversion Cycle | -312.99 | 0.00 | -555.21 | -48.07 | 557.27 |
| Days of Sales Outstanding | 285.74 | 0.00 | 0.00 | 0.00 | 15.70 |
| Days of Inventory Outstanding | 30.83 | 0.00 | 0.00 | 0.00 | 1080.16 |
| Days of Payables Outstanding | 629.57 | 0.00 | 555.21 | 48.07 | 538.60 |
| Operating Cycle | 316.58 | 0.00 | 0.00 | 0.00 | 1095.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.80 | -0.62 | -0.69 | -1.39 | -1.93 |
| Free Cash Flow Per Share | -0.81 | -0.62 | -0.69 | -1.40 | -1.95 |
| Dividend Paid and CapEx Coverage Ratio | -171.82 | -290.74 | -273.07 | -117.24 | -123.79 |
| Capital Expenditure Coverage Ratio | -171.82 | -290.74 | -273.07 | -117.24 | -123.79 |
| Operating Cash Flow Coverage Ratio | -7.19 | -4.08 | -3.61 | -0.62 | -4.81 |
| Operating Cash Flow to Sales Ratio | -154.63 | 0.00 | 0.00 | -67.16 | -38.15 |
| Free Cash Flow Yield | -5.88% | -3.59% | -5.64% | -50.44% | -13.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.71 | -18.92 | -13.93 | -1.61 | -6.51 |
| Price-to-Sales (P/S) Ratio | 2643.82 | 0.00 | 0.00 | 134.29 | 292.06 |
| Price-to-Book (P/B) Ratio | 11.47 | 8.85 | 13.25 | -41.81 | 11.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.00 | -27.88 | -17.73 | -1.98 | -7.59 |
| Price-to-Operating Cash Flow Ratio | -17.10 | -27.98 | -17.80 | -2.00 | -7.66 |
| Price-to-Earnings Growth (PEG) Ratio | -0.73 | -4.16 | 0.29 | 0.07 | -0.99 |
| Enterprise Value Multiple | -11.88 | -17.32 | -13.05 | -1.92 | -6.41 |
| Enterprise Value | 852.13M | 907.57M | 552.76M | 108.82M | 396.78M |
| EV to EBITDA | -11.88 | -17.32 | -13.05 | -1.92 | -6.41 |
| EV to Sales | 2434.67 | 0.00 | 0.00 | 155.45 | 279.82 |
| EV to Free Cash Flow | -15.65 | -24.89 | -16.67 | -2.30 | -7.28 |
| EV to Operating Cash Flow | -15.74 | -24.97 | -16.73 | -2.31 | -7.33 |
| Tangible Book Value Per Share | 1.15 | 1.90 | 0.83 | -0.22 | 1.06 |
| Shareholders’ Equity Per Share | 1.20 | 1.97 | 0.92 | -0.07 | 1.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.00 | 0.02 | 0.05 |
| Net Income Per Share | -1.08 | -0.92 | -0.88 | -1.72 | -2.28 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 1.01 | 1.01 |
| Research & Development to Revenue | 127.77 | 0.00 | 0.00 | 29.77 | 20.20 |
| SG&A to Revenue | 91.51 | 0.00 | 0.00 | 19.94 | 13.45 |
| Stock-Based Compensation to Revenue | 61.31 | 0.00 | 0.00 | 7.42 | 10.30 |
| Income Quality | 0.74 | 0.68 | 0.78 | 0.80 | 0.85 |
Currency in USD

